Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Treasury Shares (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Treasury Shares for 11 consecutive years, with $71887.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares fell 99.04% year-over-year to $71887.0, compared with a TTM value of $71887.0 through Sep 2025, down 99.04%, and an annual FY2024 reading of $7.4 million, up 28886.48% over the prior year.
  • Treasury Shares was $71887.0 for Q3 2025 at Kiora Pharmaceuticals, down from $88432.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $13.1 million in Q2 2023 and bottomed at $24094.0 in Q2 2024.
  • Average Treasury Shares over 5 years is $3.1 million, with a median of $227352.0 recorded in 2023.
  • Peak annual rise in Treasury Shares hit 28886.48% in 2024, while the deepest fall reached 99.82% in 2024.
  • Year by year, Treasury Shares stood at $168932.0 in 2021, then soared by 884.19% to $1.7 million in 2022, then plummeted by 98.47% to $25493.0 in 2023, then skyrocketed by 28886.48% to $7.4 million in 2024, then tumbled by 99.03% to $71887.0 in 2025.
  • Business Quant data shows Treasury Shares for KPRX at $71887.0 in Q3 2025, $88432.0 in Q2 2025, and $7.4 million in Q1 2025.